Hydromethylthionine

Hydromethylthionine

SCHEMBL1577040

CN(C)c1ccc2c(c1)Sc1cc(N(C)C)ccc1N2.Cl

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydromethylthionine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA known ✓ P10253 3/20 0.42
BCHE known ✓ P06276 1/20 0.40
MAOA known ✓ P21397 1/20 0.40
ACHE known ✓ P22303 1/20 0.40
PTGS1 known ✓ P23219 1/20 0.40
SLC6A2 known ✓ P23975 1/20 0.40
HTR2C known ✓ P28335 1/20 0.40
PTGS2 known ✓ P35354 1/20 0.40
SLC6A3 known ✓ Q01959 1/20 0.40
HDAC3 known ✓ O15379 1/20 0.36
HDAC4 known ✓ P56524 1/20 0.36
HDAC2 known ✓ Q92769 1/20 0.36
HDAC8 known ✓ Q9BY41 1/20 0.36
SNCA P37840 8/20 0.48
MAPT P10636 5/20 0.47
NOX1 Q9Y5S8 5/20 0.42
MEN1 O00255 3/20 0.42
MAPK1 P28482 3/20 0.42
KMT2A Q03164 3/20 0.42
TDP1 Q9NUW8 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydromethylthionine SCHEMBL29625238 1.00 SNCA (0.48) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL31159644 1.00 SNCA (0.48) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL31481566 0.98 SNCA (0.47) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL109756 0.98 SNCA (0.50) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL29356148 0.98 SNCA (0.50) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL12592446 0.98 SNCA (0.50) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL23683393 0.96 SNCA (0.48) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL12470963 0.96 SNCA (0.48) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL25194477 0.96 SNCA (0.48) SNCAMAPTNOX1GAAMEN1
Hydromethylthionine SCHEMBL31159649 0.96 SNCA (0.48) SNCAMAPTNOX1GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9320436-B2 Method and device for detecting deposits in the eye CARL ZEISS MEDITEC AG (DE) 2016-04-26 US claimed
US-20150119238-A1 METHOD AND DYE MIXTURES FOR MARKING SHAPE MEMORY POLYMERS, AND SHAPE MEMORY POLYMER ARTICLES WITH SWITCHABLE READABILITY BAM BUNDESANSTALT FUER MATERIALFORSCHUNG UND - PRUEFUNG (DE) 2015-04-30 US claimed
EP-2771392-A2 METHOD AND DYE MIXTURES FOR MARKING SHAPE MEMORY POLYMERS, AND SHAPE MEMORY POLYMER ARTICLES WITH SWITCHABLE READABILITY BAM Bundesanstalt für Materialforschung und -prüfung (DE) 2014-09-03 EP claimed
WO-2013060831-A2 METHOD AND DYE MIXTURES FOR MARKING SHAPE MEMORY POLYMERS, AND SHAPE MEMORY POLYMER ARTICLES WITH SWITCHABLE READABILITY BAM Bundesanstalt für Materialforschung und -prüfung (DE) 2013-05-02 WO claimed
US-20120229766-A1 METHOD AND DEVICE FOR DETECTING DEPOSITS IN THE EYE CARL ZEISS MEDITEC AG (DE) 2012-09-13 US claimed
WO-2011038892-A1 METHOD AND DEVICE FOR DETECTING DEPOSITS IN THE EYE CARL ZEISS MEDITEC AG (DE) 2011-04-07 WO claimed
EP-0674021-B1 Process for inhibiting metal corrosion in aquous systems SCHILLING CHEMIE GMBH U PRODUK (DE) 2000-12-06 EP claimed
EP-0674021-A1 Process for inhibiting metal corrosion in aquous systems Schilling Chemie GmbH u. Produktion KG (DE) 1995-09-27 EP claimed
EP-4613784-A1 ESTER COMPOUND-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, (METH)ACRYLIC POLYMER, AND METHOD FOR PRODUCING SAME Mitsubishi Chemical Corporation (JP) 2025-09-10 EP disclosed
EP-4613785-A1 ESTER-COMPOUND-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, AND (METH)ACRYLIC POLYMER AND METHOD FOR PRODUCING SAME Mitsubishi Chemical Corporation (JP) 2025-09-10 EP disclosed
EP-4610284-A1 MONOMER COMPOSITION, METHACRYLIC RESIN COMPOSITION AND PRODUCTION METHOD THEREFOR, AND MOLDED RESIN OBJECT Mitsubishi Chemical Corporation (JP) 2025-09-03 EP disclosed
US-20250250370-A1 METHACRYLATE-CONTAINING COMPOSITION, METHOD FOR PRODUCING METHACRYLIC ESTER, POLYMERIZABLE COMPOSITION, AND METHOD FOR PRODUCING METHACRYLIC ACID POLYMER MITSUBISHI CHEMICAL CORPORATION (JP) 2025-08-07 US disclosed
US-20250250221-A1 ESTER-COMPOUND-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, AND (METH)ACRYLIC POLYMER AND METHOD FOR PRODUCING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2025-08-07 US disclosed
US-20250250223-A1 ESTER COMPOUND-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, (METH)ACRYLIC POLYMER, AND METHOD FOR PRODUCING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2025-08-07 US disclosed
US-5721295-A CONSISTS OF WATER SOLUBLE OR WATER SWELLABLE POLYSACHHARIDE OR DERIVATIVE, A SYNTHETIC POLYMER OR COPOLYMER, AN ORGANIC MATRIX, CROSSLINKER, REACTIVE ADDITIVE AND ANTI-BLOCKING AGENT CHEMISCHE FABRIK STOCKHAUSEN GMBH (DE) 1998-02-24 US disclosed
EP-0700414-B1 POLYMER COMPOSITION, ABSORBENT MATERIAL COMPOSITION, THEIR PRODUCTION AND USE STOCKHAUSEN CHEM FAB GMBH (DE) 1997-08-06 EP disclosed
EP-0674021-A1 Process for inhibiting metal corrosion in aquous systems Schilling Chemie GmbH u. Produktion KG (DE) 1995-09-27 EP disclosed
EP-0674021-A1 Process for inhibiting metal corrosion in aquous systems Schilling Chemie GmbH u. Produktion KG (DE) 1995-09-27 EP disclosed
US-4466978-A USING ASCORBIC ACID, GLUTATHIONE AND METHYLENE BLUE Naylor, Graham John (GB) 1984-08-21 US disclosed
US-4414212-A Method of treatment of pre-menstrual syndrome Naylor, Graham J. (GB) 1983-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250250221-A1 ESTER-COMPOUND-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, AND (METH)ACRYLIC POLYMER AND METHOD FOR PRODUCING SAME ADCY6, ADCY5, AMD1 GAA 2219/4885BCHE 1060/4885MAOA 615/4885
US-20250250370-A1 METHACRYLATE-CONTAINING COMPOSITION, METHOD FOR PRODUCING METHACRYLIC ESTER, POLYMERIZABLE COMPOSITION, AND METHOD FOR PRODUCING METHACRYLIC ACID POLYMER MMAB, MAT2B, MEP1B GAA 2797/4885BCHE 2486/4885MAOA 23/4885
US-20250250223-A1 ESTER COMPOUND-CONTAINING COMPOSITION, METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, (METH)ACRYLIC POLYMER, AND METHOD FOR PRODUCING SAME MMAB, ADCY8, MAT1A GAA 1744/4885BCHE 452/4885MAOA 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.